<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312441047</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312441047</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Alveolar hemorrhage: distinct features of juvenile and adult onset systemic lupus erythematosus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Araujo</surname><given-names>DB</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312441047">1</xref>
<xref ref-type="aff" rid="aff2-0961203312441047">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Borba</surname><given-names>EF</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312441047">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Silva</surname><given-names>CA</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312441047">1</xref>
<xref ref-type="aff" rid="aff3-0961203312441047">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Campos</surname><given-names>LMA</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312441047">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pereira</surname><given-names>RMR</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312441047">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bonfa</surname><given-names>E</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312441047">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Shinjo</surname><given-names>SK</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312441047">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203312441047"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203312441047"><label>1</label>Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil</aff>
<aff id="aff2-0961203312441047"><label>2</label>Rheumatology Department, Hospital do Servidor Público Estadual de São Paulo, Brazil</aff>
<aff id="aff3-0961203312441047"><label>3</label>Pediatric Rheumatology Unit, Instituto da Criança, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil</aff>
<author-notes>
<corresp id="corresp1-0961203312441047">SK Shinjo, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Arnaldo, 455 - 3° andar, sala 3150, CEP 01246-903, São Paulo, Brazil Email: <email>samuel.shinjo@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>8</issue>
<fpage>872</fpage>
<lpage>877</lpage>
<history>
<date date-type="received"><day>5</day><month>11</month><year>2011</year></date>
<date date-type="accepted"><day>13</day><month>2</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>We compared outcomes of alveolar hemorrhage (AH) in juvenile (JSLE) and adult onset SLE (ASLE). From 263 JSLE and 1522 ASLE, the AH occurred in 13 (4.9%) and 15 (1.0%) patients, respectively (<italic>p</italic> &lt; .001). Both groups had comparable disease duration (2.6 ± 3.0 <italic>vs</italic>. 5.6 ± 7.0 years, <italic>p</italic> = .151) and median SLEDAI scores [17.5 (2 to 32) <italic>vs.</italic> 17.5 (3 to 28), <italic>p</italic> = 1.000]. At AH onset, a higher frequency of JSLE were already on a high prednisone dose ( &gt; 0.5 mg/kg/day) compared to ASLE (54% <italic>vs</italic>. 15%, <italic>p</italic> = .042). The mean drop of hemoglobin was significantly lower in JSLE (2.9 ± 0.9 <italic>vs</italic>. 5.5 ± 2.9 g/dL, <italic>p</italic> = .006). Although treatments with methylprednisolone, plasmapheresis, intravenous immunoglobulin and cyclophosphamide were similar in both groups (<italic>p</italic> &gt; .050), regarding outcomes, there was a trend in high frequency of mechanical ventilation use (85% <italic>vs</italic>. 47%, <italic>p</italic> = .055) and also significant mortality (69% <italic>vs</italic>. 13%, <italic>p</italic> = .006) in JSLE compared to ASLE. The sepsis frequency was comparable in both groups (50% <italic>vs</italic>. 27%, <italic>p</italic> = .433). We have identified that AH in JSLE has a worse outcome most likely related to respiratory failure. The AH onset in JSLE already treated with high-dose steroids raises the concern of inadequate response to this treatment and reinforces the recommendation of early aggressive alternative therapies in this group of patients.</p>
</abstract>
<kwd-group>
<kwd>Alveolar hemorrhage</kwd>
<kwd>juvenile systemic lupus erythematosus</kwd>
<kwd>mortality</kwd>
<kwd>systemic lupus erythematosus</kwd>
<kwd>pulmonary</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312441047" sec-type="intro"><title>Introduction</title>
<p>Alveolar hemorrhage (AH) in systemic lupus erythematosus (SLE) is a rare and life-threatening manifestation.<sup><xref ref-type="bibr" rid="bibr1-0961203312441047">1</xref></sup> This complication is characterized by sudden onset of dyspnoea, shortness of breath, hypoxemia, hemoptysis, and drop in serum hemoglobin level with concomitant appearance of diffuse alveolar or interstitial infiltrates.<sup><xref ref-type="bibr" rid="bibr2-0961203312441047">2</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr8-0961203312441047">8</xref></sup></p>
<p>The precise mechanism of AH in SLE is not completely defined but seems to involve immune-mediated disruption of small blood vessels with granular immune deposits<sup><xref ref-type="bibr" rid="bibr3-0961203312441047">3</xref></sup> and complement,<sup><xref ref-type="bibr" rid="bibr5-0961203312441047">5</xref></sup> uremia, pulmonary infection, and coagulopathies.<sup><xref ref-type="bibr" rid="bibr3-0961203312441047">3</xref></sup> Treatment of this severe pulmonary manifestation includes high corticosteroid doses, cytotoxic agents, intravenous human immunoglobulin, and plasmapheresis.<sup><xref ref-type="bibr" rid="bibr3-0961203312441047">3</xref></sup></p>
<p>The great majority of AH reports in SLE are isolated cases and small series, mainly in adult onset populations (ASLE),<sup><xref ref-type="bibr" rid="bibr1-0961203312441047">1</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr9-0961203312441047">9</xref></sup> whereas data regarding juvenile onset SLE (JSLE) are scarce and limited to few cases. Moreover, a systematic evaluation of AH outcomes, clinical and laboratory manifestations, and therapies in both populations is lacking in the literature.</p>
<p>Therefore, the aim of this study was to compare the AH outcome, initial clinical and laboratory features and treatment in JSLE and ASLE.</p></sec>
<sec id="sec2-0961203312441047" sec-type="methods"><title>Patients and methods</title>
<p>This retrospective study included JSLE and ASLE consecutive patients regularly followed in the Lupus Clinic of the Rheumatology Division and Pediatric Rheumatology Unit of the Children’s Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil.</p>
<p>All patients met the American College of Rheumatology<sup><xref ref-type="bibr" rid="bibr10-0961203312441047">10</xref></sup> classification criteria for SLE. Patients with disease onset before the age of 18 were classified as JSLE. The local Ethics Committee approved the study.</p>
<p>From January 1990 to January 2010, medical records of 1785 SLE patients (263 JSLE and 1522 ASLE) were extensively reviewed. AH was defined according to presence of at least three of the following pulmonary symptoms: hemoptysis, dyspnoea, tachycardia, hypoxemia and/or cough;<sup><xref ref-type="bibr" rid="bibr11-0961203312441047">11</xref>,<xref ref-type="bibr" rid="bibr12-0961203312441047">12</xref></sup> new infiltrates on chest radiograph or computed tomography scan;<sup><xref ref-type="bibr" rid="bibr11-0961203312441047">11</xref>,<xref ref-type="bibr" rid="bibr12-0961203312441047">12</xref></sup> sudden drop of hemoglobin of at least 1.5 g/dL without other source of bleeding<sup><xref ref-type="bibr" rid="bibr9-0961203312441047">9</xref></sup> and blood return on bronchoalveolar lavage (BAL) with hemosiderin-laden macrophages.<sup><xref ref-type="bibr" rid="bibr11-0961203312441047">11</xref>,<xref ref-type="bibr" rid="bibr12-0961203312441047">12</xref></sup> Acute pulmonary edema, pulmonary embolism, bronchiectasis and pulmonary infections with bleeding were excluded. Clotting disorders at AH diagnosis with international normalized ratio &gt;2.0 were also excluded.<sup><xref ref-type="bibr" rid="bibr9-0961203312441047">9</xref></sup></p>
<p>Systematic analysis at AH diagnosis included demographical data (age at disease onset, age at AH event, interval of time between SLE and AH diagnosis), gender, ethnicity, previous SLE clinical manifestations (mucocutaneous, articular, neuropsychiatric, serositis, hematological, and renal involvements), autoantibody profiles, and therapy. Lupus manifestations<sup><xref ref-type="bibr" rid="bibr10-0961203312441047">10</xref></sup> were defined as: cutaneous disease (malar or discoid rash, mucosal ulcers or photosensitivity); renal involvement (proteinuria ≥0.5 g/24 h, presence of cellular casts, hematuria with &gt;10 red blood cells/hpf excluding infection or stone, &gt;5/hpf leukocytes excluding infection, and serum creatinine ≥1.4 mg%); articular involvement (non-erosive arthritis involving two or more peripheral joints); neuropsychiatric disease (psychosis and/or seizure); serositis, and hematologic complications (hemolytic anemia, leukopenia with a white blood cell count &lt;4000/mm<sup><xref ref-type="bibr" rid="bibr3-0961203312441047">3</xref></sup> or lymphopenia &lt;1500/mm<sup><xref ref-type="bibr" rid="bibr3-0961203312441047">3</xref></sup> on two or more occasions and thrombocytopenia with platelet count &lt;100,000/mm<sup><xref ref-type="bibr" rid="bibr3-0961203312441047">3</xref></sup> in the absence of drugs).</p>
<p>SLE activity and cumulative damage at AH diagnosis were also recorded for all patients according to SLE Disease Activity Index (SLEDAI)<sup><xref ref-type="bibr" rid="bibr19-0961203312441047">19</xref></sup> and Systemic Lupus International Collaborating Clinics/ACR – Damage Index (SLICC/ACR-DI),<sup><xref ref-type="bibr" rid="bibr20-0961203312441047">20</xref></sup> respectively. Data concerning treatment at AH diagnosis, specific therapy for AH and outcome were also evaluated.</p>
<p>Antinuclear antibodies were detected by indirect immunofluorescence (IIF) using HEp-2 cells as substrate. Anti-double-stranded DNA (anti-dsDNA) antibody was also detected by IIF using <italic>Crithidia luciliae</italic>. A hemagglutination assay with rabbit thymus extract was used to determine the presence of antibodies to RNP and Sm proteins.<sup><xref ref-type="bibr" rid="bibr13-0961203312441047">13</xref></sup> Detection of autoantibodies to saline-soluble antigens Ro/SS-A and La/SS-B, was performed by counterimmunoelectrophoresis against dog spleen saline extract.<sup><xref ref-type="bibr" rid="bibr14-0961203312441047">14</xref>,<xref ref-type="bibr" rid="bibr15-0961203312441047">15</xref></sup> Nonspecific reference sera were included in each assay to determine autoantibody specificity. Presence of anticardiolipin antibodies IgG and IgM were analyzed by ELISA, as described elsewhere.<sup><xref ref-type="bibr" rid="bibr16-0961203312441047">16</xref></sup> IgG anti-ribosomal P protein antibodies were detected by Western blotting technique using purified ribosomal fraction isolated from rat hepatocytes as substrate.<sup><xref ref-type="bibr" rid="bibr17-0961203312441047">17</xref></sup> Lupus anticoagulant antibodies were detected in the blood according to the guidelines of the International Society on Thrombosis and Hemostasis.<sup><xref ref-type="bibr" rid="bibr18-0961203312441047">18</xref></sup></p>
<p>Results are presented as the mean ± standard deviation or median (range) for continuous variables and as the number (%) for categorical variables. Data were compared by Student’s <italic>t</italic>-test or by the Mann-Whitney test for continuous variables to evaluate differences between ASLE and JSLE groups with AH. For categorical variables, differences were assessed by Fisher’s exact test. <italic>p</italic> values less than 0.05 were considered significant.</p></sec>
<sec id="sec3-0961203312441047" sec-type="results"><title>Results</title>
<p>Twenty-eight patients (13 JSLE and 15 ASLE) had 30 AH events. Two adult patients had AH recurrence which was not included in this analysis. AH was diagnosed in 1.6% of SLE patients, and the frequency was significantly higher in JSLE patients (13/263 = 4.9%) compared to ASLE patients (15/1522 = 1.0%), (<italic>p</italic> &lt; .001).</p>
<p>Demographical, cumulative clinical manifestations, and autoantibody profiles of these JSLE and ASLE patients are shown in <xref ref-type="table" rid="table1-0961203312441047">Table 1</xref>. Although, as expected, JSLE had a younger age at AH diagnosis than ASLE (15.3 ± 2.7 <italic>vs</italic>. 28.7 ± 10.3 years, <italic>p &lt; </italic>.001), both groups had similar disease duration (2.6 ± 3.0 <italic>vs</italic>. 5.6 ± 7.0 years, <italic>p</italic> = .151). AH was the first SLE manifestation in two JSLE (15.4%) and in six ASLE (40.0%) patients. No differences were observed regarding gender and ethnicity (<xref ref-type="table" rid="table1-0961203312441047">Table 1</xref>).
<table-wrap id="table1-0961203312441047" position="float"><label>Table 1</label><caption><p>Demographic, cumulative clinical manifestations and autoantibodies in juvenile (JSLE) and adult (ASLE) systemic lupus erythematosus patients with alveolar hemorrhage (AH)</p></caption>
<graphic alternate-form-of="table1-0961203312441047" xlink:href="10.1177_0961203312441047-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Variables</th>
<th>JSLE</th>
<th>ASLE</th>
<th rowspan="2"><italic>P</italic></th></tr>
<tr><th>(<italic>n</italic> = 13)</th>
<th>(<italic>n</italic> = 15)</th></tr></thead>
<tbody align="left">
<tr>
<td colspan="4">Demographic data</td></tr>
<tr>
<td> Age at SLE onset, yrs</td>
<td>12.7 ± 4.2</td>
<td>23.1 ± 5.5</td>
<td>&lt; .001</td></tr>
<tr>
<td> Age at AH onset, yrs</td>
<td>15.3 ± 2.7</td>
<td>28.7 ± 10.3</td>
<td>&lt;.001</td></tr>
<tr>
<td> Time between SLE and  AH diagnosis, yrs</td>
<td>2.6 ± 3.0</td>
<td>5.6 ± 7.0</td>
<td>0.151</td></tr>
<tr>
<td> Caucasian</td>
<td>9 (69)</td>
<td>6 (40)</td>
<td>0.151</td></tr>
<tr>
<td> Female gender</td>
<td>10 (77)</td>
<td>13 (87)</td>
<td>0.639</td></tr>
<tr>
<td colspan="4">Cumulative clinical manifestations</td></tr>
<tr>
<td> Mucocutaneous involvement</td>
<td/>
<td/>
<td/></tr>
<tr>
<td>  Malar rash</td>
<td>9 (69)</td>
<td>12 (80)</td>
<td>0.670</td></tr>
<tr>
<td>  Discoid lesion</td>
<td>1 (8)</td>
<td>0</td>
<td>0.464</td></tr>
<tr>
<td>  Photosensitivity</td>
<td>9 (69)</td>
<td>9 (60)</td>
<td>0.705</td></tr>
<tr>
<td>  Oral ulcers</td>
<td>3 (23)</td>
<td>3 (20)</td>
<td>1.000</td></tr>
<tr>
<td> Arthritis</td>
<td>9 (69)</td>
<td>11 (73)</td>
<td>1.000</td></tr>
<tr>
<td colspan="4">Hematological involvement</td></tr>
<tr>
<td>  Hemolytic anemia</td>
<td>4 (31)</td>
<td>1 (7)</td>
<td>0.153</td></tr>
<tr>
<td>  Leucopenia, &lt;4000/mm<sup>3</sup></td>
<td>7 (54)</td>
<td>4 (27)</td>
<td>0.246</td></tr>
<tr>
<td>  Lymphopenia, &lt;1500/mm<sup>3</sup></td>
<td>8 (62)</td>
<td>4 (27)</td>
<td>0.135</td></tr>
<tr>
<td>  Thrombocytopenia, &lt;100,000/mm<sup>3</sup></td>
<td>3 (23)</td>
<td>4 (27)</td>
<td>1.000</td></tr>
<tr>
<td> Neuropsychiatric involvement</td>
<td>2 (15)</td>
<td>3 (20)</td>
<td>1.000</td></tr>
<tr>
<td> Serositis (pleurisies or pericarditis)</td>
<td>6 (46)</td>
<td>6 (40)</td>
<td>1.000</td></tr>
<tr>
<td> Renal involvement</td>
<td>10 (77)</td>
<td>12 (80)</td>
<td>1.000</td></tr>
<tr>
<td colspan="4">Autoantibody profiles</td></tr>
<tr>
<td> Anti-dsDNA</td>
<td>11 (85)</td>
<td>7 (47)</td>
<td>0.055</td></tr>
<tr>
<td> Anti-Sm</td>
<td>5 (39)</td>
<td>4 (27)</td>
<td>0.699</td></tr>
<tr>
<td> Anti-ribosomal P</td>
<td>2 (15)</td>
<td>3 (20)</td>
<td>1.000</td></tr>
<tr>
<td> Anti-RNP</td>
<td>2 (15)</td>
<td>5 (33)</td>
<td>0.396</td></tr>
<tr>
<td> Anti-Ro</td>
<td>1 (8)</td>
<td>2 (13)</td>
<td>1.000</td></tr>
<tr>
<td> Anti-La</td>
<td>1 (8)</td>
<td>0</td>
<td>0.464</td></tr>
<tr>
<td> IgM/IgG anticardiolipin</td>
<td>1 (8)</td>
<td>2 (13)</td>
<td>1.000</td></tr>
<tr>
<td> Lupus anticoagulant</td>
<td>0</td>
<td>0</td>
<td>1.000</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312441047"><p>Results are presented in <italic>n</italic> (%) and mean ± standard deviation (SD)</p></fn>
<fn id="table-fn2-0961203312441047"><p>AH: alveolar hemorrhage; ASLE: adult systemic lupus erythematosus; JSLE: juvenile systemic lupus erythematosus.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Cumulative clinical manifestations (mucocutaneous, articular, serositis, neuropsychiatric, hematological, and renal involvements) and frequencies of anti-Sm, anti-ribosomal P protein, anti-RNP, anti-Ro, anti-La, lupus anticoagulant, and IgM/IgG anticardiolipin) were alike in JSLE and ASLE patients with AH (<italic>p</italic> &gt; .050). The higher frequency of anti-dsDNA in JSLE patients compared to ASLE did not reach statistical significance (85% <italic>vs</italic>. 47%, <italic>p</italic> = .055) as shown in <xref ref-type="table" rid="table1-0961203312441047">Table 1</xref>.</p>
<p>Frequencies of pulmonary manifestation in JSLE and ASLE were: hemoptysis (100% <italic>vs</italic>. 73.3%, <italic>p</italic> = .102); dyspnoea (100% <italic>vs</italic>. 93.3%, <italic>p</italic> = 1.000); cough (100% <italic>vs</italic>. 40.0%, <italic>p</italic> = .001); tachycardia (100% <italic>vs</italic>. 100% <italic>p</italic> = 1.000); and hypoxemia (100% <italic>vs</italic>. 100% <italic>p</italic> = 1.000). New infiltrates were observed on chest radiograph/computed tomography scan in all patients, whereas blood return was noted on BAL in 18.1% JSLE and 36.4% ASLE patients (<italic>p</italic> = .635). The mean drop of hemoglobin was significantly lower in JSLE compared to ASLE (2.9 ± 0.9 <italic>vs</italic>. 5.5 ± 2.9 g/dL, <italic>p</italic> = .006). No differences were detected in frequencies of the other AH manifestations, such as pulmonary symptoms (hemoptysis, dyspnoea, tachycardia, hypoxemia and/or cough) and BAL with hemosiderin-laden macrophages (<italic>p</italic> &gt; .050) (<xref ref-type="table" rid="table2-0961203312441047">Table 2</xref>).
<table-wrap id="table2-0961203312441047" position="float"><label>Table 2</label><caption><p>Alveolar hemorrhage (AH) manifestations, disease activity/damage, treatment and outcomes in juvenile (JSLE) and adult (ASLE) systemic lupus erythematosus patients</p></caption>
<graphic alternate-form-of="table2-0961203312441047" xlink:href="10.1177_0961203312441047-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Variables</th>
<th>JSLE</th>
<th>ASLE</th>
<th rowspan="2"><italic>P</italic></th></tr>
<tr><th>(<italic>n</italic> = 13)</th>
<th>(<italic>n</italic> = 15)</th></tr></thead>
<tbody align="left">
<tr>
<td colspan="4">AH manifestations</td></tr>
<tr>
<td> Pulmonary symptoms</td>
<td>13 (100)</td>
<td>15 (100)</td>
<td>1.000</td></tr>
<tr>
<td> New infiltrates<xref ref-type="table-fn" rid="table-fn4-0961203312441047">*</xref></td>
<td>13 (100)</td>
<td>15 (100)</td>
<td>1.000</td></tr>
<tr>
<td> BAL</td>
<td>2 (15)</td>
<td>4 (27)</td>
<td>0.655</td></tr>
<tr>
<td> Drop of hemoglobin (g/dL)</td>
<td>2.9 ± 0.9</td>
<td>5.5 ± 2.9</td>
<td>0.006</td></tr>
<tr>
<td colspan="4">Disease activity/damage at  AH diagnosis</td></tr>
<tr>
<td> SLEDAI &gt;8</td>
<td>10 (77)</td>
<td>10 (67)</td>
<td>0.686</td></tr>
<tr>
<td> SLEDAI</td>
<td>17.5 (3–28)</td>
<td>17.5 (2–32)</td>
<td>1.000</td></tr>
<tr>
<td> SLICC-ACR/DI &gt; 1</td>
<td>3 (23)</td>
<td>4 (27)</td>
<td>1.000</td></tr>
<tr>
<td> SLICC-ACR/DI</td>
<td>0 (0–1)</td>
<td>0 (0–3)</td>
<td>1.000</td></tr>
<tr>
<td colspan="4">Current treatment at AH diagnosis</td></tr>
<tr>
<td> Prednisone</td>
<td>11/13 (85)</td>
<td>7/13 (54)</td>
<td>0.202</td></tr>
<tr>
<td>  &gt;0.5 mg/kg/day</td>
<td>7/13 (54)</td>
<td>2/13 (15)</td>
<td>0.041</td></tr>
<tr>
<td> Chloroquine diphosphate</td>
<td>11/13 (85)</td>
<td>9/13 (69)</td>
<td>0.645</td></tr>
<tr>
<td> Azathioprine</td>
<td>6/13 (46)</td>
<td>5/13 (39)</td>
<td>1.000</td></tr>
<tr>
<td> Mycophenolate mofetil</td>
<td>2/13 (15)</td>
<td>2/13 (15)</td>
<td>1.000</td></tr>
<tr>
<td> Methotrexate</td>
<td>0</td>
<td>1/13 (8)</td>
<td>1.000</td></tr>
<tr>
<td> CYC</td>
<td>1/13 (8)</td>
<td>1/13 (8)</td>
<td>1.000</td></tr>
<tr>
<td colspan="4">Treatment of AH</td></tr>
<tr>
<td> MP</td>
<td>13 (100)</td>
<td>15 (100)</td>
<td>1.000</td></tr>
<tr>
<td> Prednisone</td>
<td>13 (100)</td>
<td>15 (100)</td>
<td>1.000</td></tr>
<tr>
<td> CYC</td>
<td>9 (69)</td>
<td>7 (47)</td>
<td>0.276</td></tr>
<tr>
<td> IVIG</td>
<td>5 (39)</td>
<td>2 (13)</td>
<td>0.198</td></tr>
<tr>
<td> Plasmapheresis</td>
<td>2 (15)</td>
<td>3 (20)</td>
<td>1.000</td></tr>
<tr>
<td colspan="4">Outcome of AH</td></tr>
<tr>
<td> Mechanical ventilation</td>
<td>11 (85)</td>
<td>7 (47)</td>
<td>0.055</td></tr>
<tr>
<td> Sepsis</td>
<td>6 (50)</td>
<td>4 (27)</td>
<td>0.433</td></tr>
<tr>
<td> Macrophage activating syndrome</td>
<td>3 (23)</td>
<td>0</td>
<td>0.087</td></tr>
<tr>
<td> Death</td>
<td>9 (69)</td>
<td>2 (13)</td>
<td>0.006</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203312441047"><p>Results are presented in <italic>n</italic> (%), mean ± standard deviation (SD) or median (range).</p></fn>
<fn id="table-fn4-0961203312441047"><label>*</label><p>chest radiography and/or computed tomography; BAL: bronchoalveolar lavage with hemosiderin-laden macrophages; CYC: intravenous cyclophosphamide; IVIG: intravenous human immunoglobulin; MP: intravenous methylprednisolone; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SLICC/ACR-DI: Systemic Lupus International Collaborating Clinics/ACR – Damage Index.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Concomitant extra-pulmonary manifestations identified at AH diagnosis in JSLE and ASLE patients were nephritis (63.6% <italic>vs</italic>. 90.0%, <italic>p</italic> = .311), cutaneous manifestations (27.3% <italic>vs</italic>. 60.0%, <italic>p</italic> = .198), arthritis (18.2% <italic>vs</italic>. 50.0%, <italic>p</italic> = .183), serositis (27.3% <italic>vs</italic>. 30.0%, <italic>p</italic> = 1.000), psychosis (9.1% <italic>vs</italic>. 30.0%, <italic>p</italic> = .311) and hematological abnormalities (81.8% <italic>vs</italic>. 40.0%, <italic>p</italic> = .080). Thrombocytopenia at AH event was particularly more frequently observed in JSLE (81.8 % <italic>vs</italic>. 23.1%; <italic>p</italic> = .012).</p>
<p>Median SLEDAI scores were alike in ASLE and JSLE groups [17.5 (2 to 32) <italic>vs.</italic> 17.5 (3 to 28), <italic>p</italic> = 1.000] as well as median SLICC-ACR/DI scores (<italic>p</italic> = 1.000). Current therapy at AH diagnosis was alike in both groups (<italic>p</italic> &gt; .050), but high dose of prednisone ( &gt; 0.5 mg/kg/day) was more frequently observed in JSLE compared to ASLE (54% <italic>vs</italic>. 15%, <italic>p</italic> = .041) as shown in <xref ref-type="table" rid="table2-0961203312441047">Table 2</xref>.</p>
<p>Regarding AH treatment, all patients in both groups received intravenous methylprednisolone followed by high prednisone dose (1 mg/kg/day). Other therapies in JSLE and ASLE were: intravenous human immunoglobulin (39% <italic>vs</italic>. 13%, <italic>p</italic> = .198), plasmapheresis (20% <italic>vs</italic>. 15%, <italic>p</italic> = 1.000) and intravenous cyclophosphamide (69% <italic>vs</italic>. 47%, <italic>p</italic> = .276) (<xref ref-type="table" rid="table2-0961203312441047">Table 2</xref>).</p>
<p>Regarding outcomes, a trend of high frequency of mechanical ventilation use was observed in JSLE compared to ASLE (85% <italic>vs</italic>. 47%, <italic>p</italic> = .055). The apparent high frequency of sepsis identified in JSLE did not reach statistical significance compared to ASLE (50% <italic>vs</italic>. 27%, <italic>p</italic> = .433). Macrophage activation syndrome (MAS) with macrophage hemophagocitosis in bone marrow aspirate was only identified in JSLE compared to ASLE patients with AH diagnosis (23% <italic>vs</italic>. 0%, <italic>p</italic> = .087). Death occurred in 11 of the 28 SLE patients (39.3%) and the frequency of death was significantly higher in JSLE (69% <italic>vs</italic>. 13%, <italic>p</italic> = .006) (<xref ref-type="table" rid="table2-0961203312441047">Table 2</xref>). The causes of death are described in <xref ref-type="table" rid="table3-0961203312441047">Table 3</xref>.
<table-wrap id="table3-0961203312441047" position="float"><label>Table 3</label><caption><p>Cause of death in juvenile and adult systemic lupus erythematosus patients</p></caption>
<graphic alternate-form-of="table3-0961203312441047" xlink:href="10.1177_0961203312441047-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Juvenile SLE</th>
<th>Outcome</th>
<th>Treatment</th></tr></thead>
<tbody align="left">
<tr>
<td>DA (renal, thrombocytopenia)</td>
<td>AH, RI</td>
<td>MP, IVIG</td></tr>
<tr>
<td>DA (psychosis, pericarditis)</td>
<td>AH, RI, shock septic, dialysis</td>
<td>MP, CYC, IVIG, Atb</td></tr>
<tr>
<td>DA (renal), pneumoniae</td>
<td>AH, RI, thrombocytopenia, dialysis</td>
<td>MP, CYC, Atb</td></tr>
<tr>
<td>DA (renal)</td>
<td>AH, RI, pancytopenia</td>
<td>MP, CYC, IVIG</td></tr>
<tr>
<td>DA (cutaneous vasculitis, thrombocytopenia)</td>
<td>AH, RI, pneumomediastinum, pneumothorax, shock septic</td>
<td>MP, rituximab (2° cycle), Atb</td></tr>
<tr>
<td>DA (renal, thrombocytopenia, serositis, convulsions)</td>
<td>AH, RI</td>
<td>CYC, MP, Atb</td></tr>
<tr>
<td>DA (renal, thrombocytopenia), sepsis</td>
<td>AH, RI</td>
<td>MP, CYC</td></tr>
<tr>
<td>DA?, dyspnea</td>
<td>AH, RI</td>
<td>MP, plasmapheresis, CYC</td></tr>
<tr>
<td>DA (renal)</td>
<td>AH, RI, MAS</td>
<td>MP, IVIG</td></tr>
<tr>
<td>Adult SLE</td>
<td>Outcome</td>
<td>Treatment</td></tr>
<tr>
<td>Shock septic</td>
<td>AH</td>
<td>MP, Atb</td></tr>
<tr>
<td>Decompensated chronic renal dialysis</td>
<td>AH</td>
<td>?</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0961203312441047"><p>AH: alveolar hemorrhage; Atb: antibiotic therapy; CYC: intravenous cyclophosphamide; DA: disease activity; IVIG: intravenous human immunoglobulin; MAS: macrophage activation syndrome; MP: intravenous methylprednisolone; RI: respiratory insufficiency; SLE: systemic lupus erythematosus.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Regarding longer-term outcome, two adult SLE had AH recurrence, one of them one week after the event and the other after one month. Moreover, there were nine deaths (69.2%) out of 13 JSLE and three with currently stable disease. In relation to ASLE there were two deaths and seven with stable disease. We have no current information about one JSLE and six ASLE patients.</p></sec>
<sec id="sec4-0961203312441047" sec-type="discussion"><title>Discussion</title>
<p>The present study was the first to identify distinct features of AH in young lupus patients after the comparison of clinical manifestations, treatment, and outcome among ASLE and JSLE patients.</p>
<p>AH is a rare manifestation of SLE and most of the available reports are based on single cases and small series.<sup><xref ref-type="bibr" rid="bibr1-0961203312441047">1</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr9-0961203312441047">9</xref></sup> Recently, a study reported predictors of AH mortality in SLE but the authors have not evaluated distinctive features of pediatric lupus patients due to the small representation of these patients in their sample.<sup><xref ref-type="bibr" rid="bibr21-0961203312441047">21</xref></sup> In the present study, AH was simultaneously evaluated in a large cohort of JSLE and ASLE allowing discrimination of the unique characteristics associated with this complication in these two subgroups of patients.</p>
<p>The AH frequency identified herein was within the range previously reported in the literature (0.2–5.4%).<sup><xref ref-type="bibr" rid="bibr2-0961203312441047">2</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr7-0961203312441047">7</xref>,<xref ref-type="bibr" rid="bibr22-0961203312441047">22</xref>,<xref ref-type="bibr" rid="bibr23-0961203312441047">23</xref></sup> Of note, the frequency of AH was almost five times greater in JSLE than ASLE in our population, and as expected, young female patients seem to be more affected.<sup><xref ref-type="bibr" rid="bibr2-0961203312441047">2</xref>,<xref ref-type="bibr" rid="bibr23-0961203312441047">23</xref></sup></p>
<p>As previously observed, we find an average time between SLE onset and AH diagnosis of approximately three years in ASLE.<sup><xref ref-type="bibr" rid="bibr23-0961203312441047">23</xref></sup> Studies identified AH as one of the first manifestations of the disease in more than 30% of the cases,<sup><xref ref-type="bibr" rid="bibr11-0961203312441047">11</xref>,<xref ref-type="bibr" rid="bibr20-0961203312441047">20</xref></sup> which is confirmed by our findings in the adult population but not in juvenile patients.</p>
<p>Concomitant systemic activity was observed for the majority of patients, noticeably renal involvement and positive anti-dsDNA antibodies confirming previous reports.<sup><xref ref-type="bibr" rid="bibr7-0961203312441047">7</xref>,<xref ref-type="bibr" rid="bibr20-0961203312441047">20</xref>,<xref ref-type="bibr" rid="bibr23-0961203312441047">23</xref></sup> Liu et al.<sup><xref ref-type="bibr" rid="bibr7-0961203312441047">7</xref></sup> and Abud-Mendoza et al.<sup><xref ref-type="bibr" rid="bibr20-0961203312441047">20</xref></sup> described active nephritis in 100% and 66% of their SLE patients with AH,<sup><xref ref-type="bibr" rid="bibr7-0961203312441047">7</xref>,<xref ref-type="bibr" rid="bibr20-0961203312441047">20</xref></sup> and neuropsychiatric manifestations in 60% and 58%. In contrast to their findings, a low frequency of neuropsychiatric manifestation was observed in our cohort in both groups. The restricted definition of SLEDAI criteria used in the present study is the most likely explanation for this discrepancy.</p>
<p>Prompt recognition of AH seems to be a major step for a better prognosis. Dyspnoea, hypoxemia, hemoptysis, and appearance of diffuse alveolar or interstitial infiltrates are indeed highly suspicious for AH and were observed in similar frequencies in both groups.<sup><xref ref-type="bibr" rid="bibr11-0961203312441047">11</xref>,<xref ref-type="bibr" rid="bibr12-0961203312441047">12</xref></sup> Interestingly, a drop in serum hemoglobin was a distinct parameter, with a significantly more pronounced decrease in ASLE, raising the possibility that the better outcome for this group of patients may be related to an earlier diagnosis facilitated by the severity of this clinical finding.</p>
<p>AH treatment remains empirical due to the lack of randomized trials and includes corticosteroids associated with cytotoxic agents, human immunoglobulin and/or plasmapheresis.<sup><xref ref-type="bibr" rid="bibr3-0961203312441047">3</xref></sup> In our study, all SLE patients received intravenous methylprednisolone and almost half of these patients also received either plasmapheresis or intravenous human immunoglobulin, followed by immunosuppressor (mainly cyclophosphamide). High-dose pulse corticosteroids followed by intravenous cyclophosphamide seems to be the cornerstone of treatment and plasmapheresis has been considered in refractory cases.</p>
<p>As a consequence of immunosuppressive therapy, SLE patients are prone to severe infections. In our study, almost a quarter of ASLE patients and half of JSLE patients had sepsis. This finding may account for the worst prognosis observed in JSLE with AH. In fact, Santos-Ocampo et al.<sup><xref ref-type="bibr" rid="bibr2-0961203312441047">2</xref></sup> reported a 100% survival in seven patients with AH and SLE who received high-spectrum antibiotic treatment at the beginning of their management.<sup><xref ref-type="bibr" rid="bibr2-0961203312441047">2</xref></sup></p>
<p>In addition, MAS was only detected in approximately one quarter of JSLE, but is considered a severe, potentially life-threatening complication that could also be responsible for the mortality in our study. Among juvenile rheumatic diseases, MAS occurs more frequently in systemic onset juvenile idiopathic arthritis, as reported previously in our patients.<sup><xref ref-type="bibr" rid="bibr24-0961203312441047">24</xref>,<xref ref-type="bibr" rid="bibr25-0961203312441047">25</xref></sup> However, recently this syndrome has been increasingly reported in JSLE,<sup><xref ref-type="bibr" rid="bibr26-0961203312441047">26</xref>,<xref ref-type="bibr" rid="bibr27-0961203312441047">27</xref></sup> with an estimated prevalence of 0.9–4.6%.<sup><xref ref-type="bibr" rid="bibr28-0961203312441047">28</xref></sup> Since MAS can determine a rapidly fatal course, prompt recognition and immediate therapeutic intervention are imperative. Despite this, two of our three JSLE patients with MAS died.</p>
<p>Previous studies support the concept that JSLE is more active and associated with more accrual damage than ASLE.<sup><xref ref-type="bibr" rid="bibr29-0961203312441047">29</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr32-0961203312441047">32</xref></sup> Hoffman et al.,<sup><xref ref-type="bibr" rid="bibr32-0961203312441047">32</xref></sup> for instance, reported more renal involvement and encephalopathy, and greater presence of anti-ribosomal P, anti-dsDNA and antihistone antibodies in juvenile than adult-onset SLE patients. Brunner et al.<sup><xref ref-type="bibr" rid="bibr29-0961203312441047">29</xref></sup> showed that juvenile patients had more active disease at presentation and over time than ASLE, especially active renal disease. Moreover, children received more intensive drug therapy and accrue more damage, often related to steroid toxicity.<sup><xref ref-type="bibr" rid="bibr29-0961203312441047">29</xref></sup> Costallat and Coimbra<sup><xref ref-type="bibr" rid="bibr30-0961203312441047">30</xref></sup> demonstrated that juvenile patients had a poorer prognosis with more seizures, gastrointestinal involvement, nephrotic syndrome, and a higher rate of mortality than ASLE patients. In contrast to these authors, our patients were comparable, in respect of clinical and autoantibody profiles. It may be that the focus of the present study is alveolar hemorrhage and, therefore, both groups had severe-onset disease course and were comparable.</p>
<p>The overall mortality observed herein was near 40%. That is in accordance with previous reports (ranging from 36% to 90%)<sup><xref ref-type="bibr" rid="bibr4-0961203312441047">4</xref>,<xref ref-type="bibr" rid="bibr5-0961203312441047">5</xref>,<xref ref-type="bibr" rid="bibr7-0961203312441047">7</xref>,<xref ref-type="bibr" rid="bibr11-0961203312441047">11</xref>,<xref ref-type="bibr" rid="bibr20-0961203312441047">20</xref>,<xref ref-type="bibr" rid="bibr22-0961203312441047">22</xref></sup> but in the present study we clearly identified a decrease in the survival in young SLE patients with AH. Since the total number of deaths was small, it was not possible to compare the mortality causes between JSLE and ASLE. However, our study showed that, in the case of JSLE, the mortality was associated with disease activity and respiratory insufficiency secondarily to AH. In contrast, the death in two ASLE was more related to systemic infection (septic shock) and decompensated chronic renal dialysis.</p>
<p>In conclusion, AH is rarely observed in the early stages of SLE and has an unpredictable course but seems to be more prevalent and fatal in JSLE, most likely related to respiratory failure. A high frequency of AH onset in JSLE already treated with high-dose steroids, raises the concern of inadequate response to this treatment and reinforces the recommendation of early aggressive alternative therapies in these patients.</p></sec>
</body>
<back>
<sec id="sec5-0961203312441047"><title>Funding</title>
<p>This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ grants #303165/2008-1 to EFB, #300248/2008-3 to CAS, #300559/2009-7 to RMRP, #301411/2009-3 to EB) and Federico Foundation Grant (to EFB, CAS, RMRP, EB, SKS).</p></sec>
<sec id="sec6-0961203312441047"><title>Conflict of interest</title>
<p>None declared.</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312441047"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Osler</surname><given-names>W</given-names></name></person-group>. <article-title>On the visceral manifestations of the erythema group of diseases</article-title>. <source>Am J Med Sci</source> <year>1904</year>; <volume>127</volume>: <fpage>1</fpage>–<lpage>23</lpage>.</citation></ref>
<ref id="bibr2-0961203312441047"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santos-Ocampo</surname><given-names>AS</given-names></name><name><surname>Mandell</surname><given-names>BF</given-names></name><name><surname>Fessler</surname><given-names>BJ</given-names></name></person-group>. <article-title>Alveolar hemorrhage in systemic lupus erythematosus – presentation and management</article-title>. <source>Chest</source> <year>2000</year>; <volume>118</volume>: <fpage>1083</fpage>–<lpage>1090</lpage>.</citation></ref>
<ref id="bibr3-0961203312441047"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwab</surname><given-names>EP</given-names></name><name><surname>Schumacher</surname><given-names>HR</given-names></name><name><surname>Freundlich</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Pulmonary alveolar hemorrhage in systemic lupus erythematosus</article-title>. <source>Semin Arthritis Rheum</source> <year>1993</year>; <volume>23</volume>: <fpage>8</fpage>–<lpage>15</lpage>.</citation></ref>
<ref id="bibr4-0961203312441047"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zamora</surname><given-names>MR</given-names></name><name><surname>Warner</surname><given-names>ML</given-names></name><name><surname>Tuder</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Diffuse alveolar hemorrhage and systemic lupus erythematosus: clinical presentation, histology, survival and outcome</article-title>. <source>Medicine</source> <year>1997</year>; <volume>76</volume>: <fpage>192</fpage>–<lpage>202</lpage>.</citation></ref>
<ref id="bibr5-0961203312441047"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barile</surname><given-names>LA</given-names></name><name><surname>Jara</surname><given-names>LJ</given-names></name><name><surname>Medina-Rodriguez</surname></name><etal/></person-group>. <article-title>Pulmonary hemorrhage in systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>1997</year>; <volume>6</volume>: <fpage>445</fpage>–<lpage>448</lpage>.</citation></ref>
<ref id="bibr6-0961203312441047"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>WH</given-names></name><name><surname>Thumboo</surname><given-names>J</given-names></name><name><surname>Boey</surname><given-names>ML</given-names></name></person-group>. <article-title>Pulmonary hemorrhage in oriental patients with systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>1997</year>; <volume>6</volume>: <fpage>713</fpage>–<lpage>716</lpage>.</citation></ref>
<ref id="bibr7-0961203312441047"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>MF</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Weng</surname><given-names>TH</given-names></name><etal/></person-group>. <article-title>Clinical experience of 13 cases with severe pulmonary hemorrhage in systemic lupus erythematosus with active nephritis</article-title>. <source>Scand J Rheumatol</source> <year>1998</year>; <volume>27</volume>: <fpage>291</fpage>–<lpage>295</lpage>.</citation></ref>
<ref id="bibr8-0961203312441047"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marino</surname><given-names>CT</given-names></name><name><surname>Pertschuk</surname><given-names>LP</given-names></name></person-group>. <article-title>Pulmonary hemorrhage in systemic lupus erythematosus</article-title>. <source>Arch Intern Med</source> <year>1991</year>; <volume>141</volume>: <fpage>201</fpage>–<lpage>203</lpage>.</citation></ref>
<ref id="bibr9-0961203312441047"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwok</surname><given-names>SK</given-names></name><name><surname>Moon</surname><given-names>SJ</given-names></name><name><surname>Ju</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>Diffuse alveolar hemorrhage in systemic lupus erythematosus: risk factors and clinical outcome: results from affiliated hospitals of Catholic University of Korea</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage>102</fpage>–<lpage>107</lpage>.</citation></ref>
<ref id="bibr10-0961203312441047"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>.</citation></ref>
<ref id="bibr11-0961203312441047"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JG</given-names></name><name><surname>Joo</surname><given-names>KW</given-names></name><name><surname>Chung</surname><given-names>WK</given-names></name><etal/></person-group>. <article-title>Diffuse alveolar hemorrhage in lupus nephritis</article-title>. <source>Clin Nephrol</source> <year>2000</year>; <volume>54</volume>: <fpage>282</fpage>–<lpage>288</lpage>.</citation></ref>
<ref id="bibr12-0961203312441047"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>D</given-names></name><name><surname>Ginzler</surname><given-names>E</given-names></name><name><surname>Goldsmith</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1996</year>; <volume>39</volume>: <fpage>363</fpage>–<lpage>369</lpage>.</citation></ref>
<ref id="bibr13-0961203312441047"><label>13</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>EM</given-names></name><name><surname>Peebles</surname><given-names>C</given-names></name></person-group>. <article-title>Quantitation of antibodies to Sm antigen and nuclear ribonucleoprotein by hemagglutination</article-title>. In: <person-group person-group-type="editor"><name><surname>Rose</surname><given-names>NR</given-names></name><name><surname>Friedman</surname><given-names>H</given-names></name></person-group> (eds). <source>Manual of Clinical Immunology</source>, <edition>2nd edn</edition>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Society of Microbiology</publisher-name>, <year>1980</year>; <fpage>866</fpage>–<lpage>870</lpage>.</citation></ref>
<ref id="bibr14-0961203312441047"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurata</surname><given-names>N</given-names></name><name><surname>Tan</surname><given-names>EM</given-names></name></person-group>. <article-title>Identification of antibodies to nuclear acidic antigens by counterimmunoelectrophoresis</article-title>. <source>Arthritis Rheum</source> <year>1976</year>; <volume>19</volume>: <fpage>574</fpage>–<lpage>580</lpage>.</citation></ref>
<ref id="bibr15-0961203312441047"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elkon</surname><given-names>KB</given-names></name><name><surname>Culhane</surname><given-names>L</given-names></name></person-group>. <article-title>Partial immunochemical characterization of the Ro and La proteins using antibodies from patients with the sicca syndrome and lupus erythematosus</article-title>. <source>J Immunol</source> <year>1984</year>; <volume>132</volume>: <fpage>2350</fpage>–<lpage>2356</lpage>.</citation></ref>
<ref id="bibr16-0961203312441047"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gharavi</surname><given-names>AE</given-names></name><name><surname>Harris</surname><given-names>EN</given-names></name><name><surname>Asherson</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>Anticardiolipin antibodies: isotype distribution and phospholipid specificity</article-title>. <source>Ann Rheum Dis</source> <year>1987</year>; <volume>46</volume>: <fpage>1</fpage>–<lpage>6</lpage>.</citation></ref>
<ref id="bibr17-0961203312441047"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonfá</surname><given-names>E</given-names></name><name><surname>Golombek</surname><given-names>SJ</given-names></name><name><surname>Kaufman</surname><given-names>LD</given-names></name><etal/></person-group>. <article-title>Association between lupus psychosis and anti-ribosomal P protein antibodies</article-title>. <source>N Engl J Med</source> <year>1987</year>; <volume>317</volume>: <fpage>265</fpage>–<lpage>271</lpage>.</citation></ref>
<ref id="bibr18-0961203312441047"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brandt</surname><given-names>JT</given-names></name><name><surname>Triplett</surname><given-names>DA</given-names></name><name><surname>Alving</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Criteria for diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH</article-title>. <source>Thromb Haemost</source> <year>1995</year>; <volume>74</volume>: <fpage>1185</fpage>–<lpage>1190</lpage>.</citation></ref>
<ref id="bibr19-0961203312441047"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bombardier</surname><given-names>C</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><etal/></person-group>. <article-title>Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE</article-title>. <source>Arthritis Rheum</source> <year>1992</year>; <volume>35</volume>: <fpage>630</fpage>–<lpage>640</lpage>.</citation></ref>
<ref id="bibr20-0961203312441047"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abud-Mendoza</surname><given-names>C</given-names></name><name><surname>Diaz-Jouanen</surname><given-names>E</given-names></name><name><surname>Alarcón-Segovia</surname><given-names>D</given-names></name></person-group>. <article-title>Fatal pulmonary hemorrhage in systemic lupus erythematosus. Occurrence without hemoptysis</article-title>. <source>J Rheumatol</source> <year>1985</year>; <volume>12</volume>: <fpage>558</fpage>–<lpage>561</lpage>.</citation></ref>
<ref id="bibr21-0961203312441047"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martínez-Martínez</surname><given-names>MU</given-names></name><name><surname>Abud-Mendoza</surname><given-names>C</given-names></name></person-group>. <article-title>Predictors of mortality in diffuse alveolar haemorrhage associated with systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage>568</fpage>–<lpage>574</lpage>.</citation></ref>
<ref id="bibr22-0961203312441047"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eagen</surname><given-names>JW</given-names></name><name><surname>Memoli</surname><given-names>VA</given-names></name><name><surname>Roberts</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Pulmonary hemorrhage in systemic lupus erythematosus</article-title>. <source>Medicine</source> <year>1978</year>; <volume>57</volume>: <fpage>545</fpage>–<lpage>560</lpage>.</citation></ref>
<ref id="bibr23-0961203312441047"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Badsha</surname><given-names>H</given-names></name><name><surname>Teh</surname><given-names>CL</given-names></name><name><surname>King</surname><given-names>KO</given-names></name><etal/></person-group>. <article-title>Pulmonary hemorrhage in systemic lupus erythematosus</article-title>. <source>Semin Arthritis Rheum</source> <year>2004</year>; <volume>33</volume>: <fpage>414</fpage>–<lpage>421</lpage>.</citation></ref>
<ref id="bibr24-0961203312441047"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>CA</given-names></name><name><surname>Silva</surname><given-names>CH</given-names></name><name><surname>Robazzi</surname><given-names>TC</given-names></name><etal/></person-group>. <article-title>Macrophage activation syndrome associated with systemic juvenile idiopathic arthritis</article-title>. <source>J Pediatr <italic>(Rio J)</italic></source> <year>2004</year>; <volume>80</volume>: <fpage>517</fpage>–<lpage>522</lpage>.</citation></ref>
<ref id="bibr25-0961203312441047"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aikawa</surname><given-names>NE</given-names></name><name><surname>Carvalho</surname><given-names>JF</given-names></name><name><surname>Bonfá</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Macrophage activation syndrome associated with etanercept in a child with systemic onset juvenile idiopathic arthritis</article-title>. <source>Isr Med Assoc J</source> <year>2009</year>; <volume>11</volume>: <fpage>635</fpage>–<lpage>636</lpage>.</citation></ref>
<ref id="bibr26-0961203312441047"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parodi</surname><given-names>A</given-names></name><name><surname>Davi</surname><given-names>S</given-names></name><name><surname>Pringe</surname><given-names>AB</given-names></name><etal/></person-group>. <article-title>Macrophage activation syndrome in juvenile systemic lupus erythematosus. A multinational multicenter study of thirty-eight patients</article-title>. <source>Arthritis Rheum</source> <year>2009</year>; <volume>60</volume>: <fpage>3388</fpage>–<lpage>3399</lpage>.</citation></ref>
<ref id="bibr27-0961203312441047"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campos</surname><given-names>LM</given-names></name><name><surname>Omori</surname><given-names>CH</given-names></name><name><surname>Lotito</surname><given-names>AP</given-names></name><etal/></person-group>. <article-title>Acute pancreatitis in juvenile systemic lupus erythematosus: a manifestation of macrophage activation syndrome?</article-title> <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage>1654</fpage>–<lpage>1658</lpage>.</citation></ref>
<ref id="bibr28-0961203312441047"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fukaya</surname><given-names>S</given-names></name><name><surname>Yasuda</surname><given-names>S</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases</article-title>. <source>Rheumatology <italic>(Oxford)</italic></source> <year>2008</year>; <volume>47</volume>: <fpage>1686</fpage>–<lpage>1691</lpage>.</citation></ref>
<ref id="bibr29-0961203312441047"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>HI</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Ibañez</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2008</year>; <volume>58</volume>: <fpage>556</fpage>–<lpage>562</lpage>.</citation></ref>
<ref id="bibr30-0961203312441047"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Costallat</surname><given-names>LT</given-names></name><name><surname>Coimbra</surname><given-names>AM</given-names></name></person-group>. <article-title>Systemic lupus erythematosus: clinical and laboratory aspects related to age at disease onset</article-title>. <source>Clin Exp Rheumatol</source> <year>1994</year>; <volume>12</volume>: <fpage>603</fpage>–<lpage>607</lpage>.</citation></ref>
<ref id="bibr31-0961203312441047"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tucker</surname><given-names>LB</given-names></name><name><surname>Menon</surname><given-names>S</given-names></name><name><surname>Schaller</surname><given-names>JG</given-names></name><etal/></person-group>. <article-title>Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome</article-title>. <source>Br J Rheumatol</source> <year>1995</year>; <volume>34</volume>: <fpage>866</fpage>–<lpage>872</lpage>.</citation></ref>
<ref id="bibr32-0961203312441047"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>IEA</given-names></name><name><surname>Lauwerys</surname><given-names>BR</given-names></name><name><surname>De Keyser</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source> <year>2009</year>; <volume>68</volume>: <fpage>412</fpage>–<lpage>415</lpage>.</citation></ref>
</ref-list>
</back>
</article>